Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Recommendation of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average recommendation of “Hold” from the twenty-one analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $125.05.

Several equities analysts have recently commented on the company. Piper Sandler lowered Zimmer Biomet from an “overweight” rating to a “neutral” rating and cut their price target for the company from $140.00 to $115.00 in a research note on Monday, July 1st. Truist Financial restated a “hold” rating and issued a $112.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a report on Friday, September 13th. Raymond James dropped their price objective on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. TD Cowen reduced their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research note on Friday, September 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, September 17th.

Zimmer Biomet Trading Down 1.4 %

ZBH stock opened at $104.19 on Friday. The company has a market capitalization of $21.22 billion, a PE ratio of 22.55, a P/E/G ratio of 1.94 and a beta of 1.02. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63. Zimmer Biomet has a 12 month low of $102.00 and a 12 month high of $133.90. The firm’s 50-day moving average is $109.33 and its 200 day moving average is $114.30.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the previous year, the firm posted $1.82 earnings per share. The company’s revenue was up 3.9% on a year-over-year basis. On average, research analysts anticipate that Zimmer Biomet will post 8 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Institutional Trading of Zimmer Biomet

Several large investors have recently added to or reduced their stakes in ZBH. OLD Point Trust & Financial Services N A purchased a new stake in Zimmer Biomet in the fourth quarter valued at approximately $26,000. Ables Iannone Moore & Associates Inc. purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at $30,000. Crewe Advisors LLC acquired a new stake in shares of Zimmer Biomet in the first quarter worth $31,000. Family Firm Inc. purchased a new position in shares of Zimmer Biomet during the second quarter worth $33,000. Finally, J.Safra Asset Management Corp grew its holdings in Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 235 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.